Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).

Authors: Sung-Bae Kim, Binghe Xu, Tao Sun, Qingyuan Zhang, Sanja Kostic, Xiaojia Wang, Zhongsheng Tong, Shusen Wang, Jingfen Wang, Wei Li, Keun Seok Lee, Yong Wha Moon, Myoung Joo Kang, Xichun Hu, Tae-Yong Kim, Dusan Milenkovic, Jae Hong Seo, Jee Hung Kim, Ji Eun Lee, Joohyuk Sohn

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.1007

Source: Full article

---

Abstract

1007